Pathogenesis of Hypertension

Hypertension: A Companion to Braunwald's Heart Disease

Volumn , Issue , 2018, Pages 33-51

  Hall, Michael E ^a   Hall, John E ^a  

^a UNIVERSITY OF MISSISSIPPI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 85051104641     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-0-323-42973-3.00005-6     Document Type: Chapter

References (206)

1. Garrison R.J., Kannel W.B., Stokes J., et al. Incidence and precursors of hypertension in young adults: the Framingham Offspring Study. Prev Med 1987, 16:235-251.
2. Hall J.E., do Carmo J.M., da Silva A.A., et al. Obesity-induced hypertension: interaction of neurohumoral and renal mechanisms. Circ Res 2015, 116:991-1006.
3. Hall J.E., Granger J.P., do Carmo J.M., et al. Hypertension: physiology and pathophysiology. Compr Physiol 2012, 2:2393-2442.
4. Hall J.E. Renal Dysfunction, Rather Than Nonrenal Vascular Dysfunction, Mediates Salt-Induced Hypertension. Circulation 2016, 133:894-906.
5. Cowley A.W. The concept of autoregulation of total blood flow and its role in hypertension. Am J Med 1980, 68:906-916.
6. Carlstrom M., Wilcox C.S., Arendshorst W.J. Renal autoregulation in health and disease. Physiol Rev 2015, 95:405-511.
7. Coleman T.G., Hall J.E. Systemic hemodynamics and regional blood flow regulation. Hypertension Primer 2008, 129-132. American Heart Association, Washington, DC. J.L. Izzo, D.A. Sica, H.C. Black (Eds.).
8. 23Na MRI at 7.0 T. NMR Biomed 2015, 28:54-62.
9. Kotchen T.A., Cowley A.W., Frohlich E.D. Salt in health and disease-a delicate balance. N Engl J Med 2013, 368:1229-1237.
10. Averina V.A., Othmer H.G., Fink G.D., et al. A mathematical model of salt-sensitive hypertension: the neurogenic hypothesis. J Physiol 2015, 593:3065-3075.
11. Hall J.E. The kidney, hypertension, and obesity. Hypertension 2003, 41:625-633.
12. Guyton A.C. The surprising kidney-fluid mechanism for pressure control-its infinite gain!. Hypertension 1990, 16:725-730.
13. Hall J.E., Mizelle H.L., Hildebrandt D.A., et al. Abnormal pressure natriuresis. A cause or a consequence of hypertension?. Hypertension 1990, 15:547-559.
14. Mizelle H.L., Montani J.P., Hester R.L., et al. Role of pressure natriuresis in long-term control of renal electrolyte excretion. Hypertension 1993, 22:102-110.
15. Hall J.E., Granger J.P., Smith M.J., et al. Role of renal hemodynamics and arterial pressure in aldosterone "escape". Hypertension 1984, 6:I183-I192.
16. Hall J.E., Granger J.P., Hester R.L., et al. Mechanisms of escape from sodium retention during angiotensin II hypertension. Am J Physiol 1984, 246:F627-F634.
17. Hall J.E., Montani J.P., Woods L.L., et al. Renal escape from vasopressin: role of pressure diuresis. Am J Physiol 1986, 250:F907-F916.
18. Hall J.E., Mizelle H.L., Woods L.L., et al. Pressure natriuresis and control of arterial pressure during chronic norepinephrine infusion. J Hypertens 1988, 6:723-731.
19. Woods L.L., Mizelle H.L., Hall J.E. Control of sodium excretion in NE-ACTH hypertension: role of pressure natriuresis. Am J Physiol 1988, 255:R894-R900.
20. Brands M.W., Hall J.E. Renal perfusion pressure is an important determinant of sodium and calcium excretion in DOC-salt hypertension. Am J Hypertens 1998, 11:1199-1207.
21. Cowley A.W. Long-term control of arterial blood pressure. Physiol Rev 1992, 72:231-300.
22. Guyton A.C. Arterial pressure and hypertension: circulatory physiology III 1980, 1-564. WB Saunders, Philadelphia.
23. Schrier R.W., Howard R.L. Unifying hypothesis of sodium and water regulation in health and disease. Hypertension 1991, 18:III164-III168.
24. Appel L.J., Frohlich E.D., Hall J.E., et al. The importance of population-wide sodium reduction as a means to prevent cardiovascular disease and stroke: a call to action from the American Heart Association. Circulation 2011, 123:1138-1143.
25. Whelton P.K., Appel L.J., Sacco R.L., et al. Sodium, blood pressure, and cardiovascular disease: further evidence supporting the American Heart Association sodium reduction recommendations. Circulation 2012, 126:2880-2889.
26. Kawasaki T., Delea C.S., Bartter F.C., et al. The effect of high-sodium and low-sodium intakes on blood pressure and other related variables in human subjects with idiopathic hypertension. Am J Med 1978, 64:193-198.
27. Rossier B.C., Staub O., Hummler E. Genetic dissection of sodium and potassium transport along the aldosterone-sensitive distal nephron: importance in the control of blood pressure and hypertension. FEBS Lett 2013, 587:1929-1941.
28. Lifton R.P., Gharavi A.G., Geller D.S. Molecular mechanisms of human hypertension. Cell 2001, 104:545-556.
29. Langston J.B., Guyton A.C., Douglas B.H., et al. Effect of changes in salt intake on arterial pressure and renal function in partially nephrectomized dogs. Circ Res 1963, 12:508-512.
30. Koomans H.A., Roos J.C., Boer P., et al. Salt sensitivity of blood pressure in chronic renal failure. Evidence for renal control of body fluid distribution in man. Hypertension 1982, 4:190-197.
31. Johnson R.J., Lanaspa M.A., Gabriela Sanchez-Lozada L., et al. The discovery of hypertension: evolving views on the role of the kidneys, and current hot topics. Am J Physiol Renal Physiol 2015, 308:F167-F178.
32. Hall J.E. Control of sodium excretion by angiotensin II: intrarenal mechanisms and blood pressure regulation. Am J Physiol 1986, 250:R960-R972.
33. Hall J.E., Guyton A.C., Smith M.J., et al. Blood pressure and renal function during chronic changes in sodium intake: role of angiotensin. Am J Physiol 1980, 239:F271-F280.
34. Kohan D.E. Role of collecting duct endothelin in control of renal function and blood pressure. Am J Physiol Regul Integr Comp Physiol 2013, 305:R659-R668.
35. Kohan D.E., Rossi N.F., Inscho E.W., et al. Regulation of blood pressure and salt homeostasis by endothelin. Physiol Rev 2011, 91:1-77.
36. Ge Y., Bagnall A., Stricklett P.K., et al. Collecting duct-specific knockout of the endothelin B receptor causes hypertension and sodium retention. Am J Physiol Renal Physiol 2006, 291:F1274-F1280.
37. Ge Y., Bagnall A., Stricklett P.K., et al. Combined knockout of collecting duct endothelin A and B receptors causes hypertension and sodium retention. Am J Physiol Renal Physiol 2008, 295:F1635-F1640.
38. Ahn D., Ge Y., Stricklett P.K., et al. Collecting duct-specific knockout of endothelin-1 causes hypertension and sodium retention. J Clin Invest 2004, 114:504-511.
39. Speed J.S., Heimlich J.B., Hyndman K.A., et al. Endothelin-1 as a master regulator of whole-body Na+ homeostasis. FASEB J 2015.
40. Hoorn E.J., Nelson J.H., McCormick J.A., et al. The WNK kinase network regulating sodium, potassium, and blood pressure. J Am Soc Nephrol 2011, 22:605-614.
41. Botero-Velez M., Curtis J.J., Warnock D.G. Brief report: liddle's syndrome revisited-a disorder of sodium reabsorption in the distal tubule. N Engl J Med 1994, 330:178-181.
42. Chapman K., Holmes M., Seckl J. 11beta-hydroxysteroid dehydrogenases: intracellular gate-keepers of tissue glucocorticoid action. Physiol Rev 2013, 93:1139-1206.
43. Palermo M., Cossu M., Shackleton C.H. Cure of apparent mineralocorticoid excess by kidney transplantation. N Engl J Med 1998, 339:1787-1788.
44. Khattab A.M., Shackleton C.H., Hughes B.A., et al. Remission of hypertension and electrolyte abnormalities following renal transplantation in a patient with apparent mineralocorticoid excess well documented throughout childhood. J Pediatr Endocrinol Metab 2014, 27:17-21.
45. Hall J.E. Renal function in one-kidney, one-clip hypertension and low renin essential hypertension. Am J Hypertens 1991, 4:523S-533S.
46. Toka O., Tank J., Schachterle C., et al. Clinical effects of phosphodiesterase 3A mutations in inherited hypertension with brachydactyly. Hypertension 2015, 66:800-808.
47. Schuster H., Toka O., Toka H.R., et al. A cross-over medication trial for patients with autosomal-dominant hypertension with brachydactyly. Kidney Int 1998, 53:167-172.
48. Jordan J., Toka H.R., Heusser K., et al. Severely impaired baroreflex-buffering in patients with monogenic hypertension and neurovascular contact. Circulation 2000, 102:2611-2618.
49. Weinberger M.H. Salt sensitivity of blood pressure in humans. Hypertension 1996, 27:481-490.
50. Weinberger M.H., Fineberg N.S., Fineberg S.E., et al. Salt sensitivity, pulse pressure, and death in normal and hypertensive humans. Hypertension 2001, 37:429-432.
51. Hall J.E., Guyton A.C., Brands M.W. Pressure-volume regulation in hypertension. Kidney Int Suppl 1996, 55:S35-S41.
52. Campese V.M. Salt sensitivity in hypertension. Renal and cardiovascular implications. Hypertension 1994, 23:531-550.
53. Hall J.E., Brands M.W., Henegar J.R. Angiotensin II and long-term arterial pressure regulation: the overriding dominance of the kidney. J Am Soc Nephrol 1999, 10(Suppl 12):S258-S265.
54. Carey R.M., Wang Z.Q., Siragy H.M. Role of the angiotensin type 2 receptor in the regulation of blood pressure and renal function. Hypertension 2000, 35:155-163.
55. Crowley S.D., Coffman T.M. The inextricable role of the kidney in hypertension. J Clin Invest 2014, 124:2341-2347.
56. Crowley S.D., Gurley S.B., Herrera M.J., et al. Angiotensin II causes hypertension and cardiac hypertrophy through its receptors in the kidney. Proc Natl Acad Sci U S A 2006, 103:17985-17990.
57. Eng E., Veniant M., Floege J., et al. Renal proliferative and phenotypic changes in rats with two-kidney, one-clip Goldblatt hypertension. Am J Hypertens 1994, 7:177-185.
58. Rossier B.C., Baker M.E., Studer R.A. Epithelial sodium transport and its control by aldosterone: the story of our internal environment revisited. Physiol Rev 2015, 95:297-340.
59. Funder J.W. The nongenomic actions of aldosterone. Endocr Rev 2005, 26:313-321.
60. Calhoun D.A. Hyperaldosteronism as a common cause of resistant hypertension. Annu Rev Med 2013, 64:233-247.
61. de S.F., Muxfeldt E., Fiszman R., et al. Efficacy of spironolactone therapy in patients with true resistant hypertension. Hypertension 2010, 55:147-152.
62. Ferrario C.M., Schiffrin E.L. Role of mineralocorticoid receptor antagonists in cardiovascular disease. Circ Res 2015, 116:206-213.
63. Williams B., MacDonald T.M., Morant S., et al. Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial. Lancet 2015, 386:2059-2068.
64. Fujita T. Mechanism of salt-sensitive hypertension: focus on adrenal and sympathetic nervous systems. J Am Soc Nephrol 2014, 25:1148-1155.
65. Grassi G., Mark A., Esler M. The sympathetic nervous system alterations in human hypertension. Circ Res 2015, 116:976-990.
66. DiBona G.F. Sympathetic nervous system and hypertension. Hypertension 2013, 61:556-560.
67. DiBona G.F. Physiology in perspective: the Wisdom of the Body. Neural control of the kidney. Am J Physiol Regul Integr Comp Physiol 2005, 289:R633-R641.
68. Hering D., Marusic P., Walton A.S., et al. Sustained sympathetic and blood pressure reduction 1 year after renal denervation in patients with resistant hypertension. Hypertension 2014, 64:118-124.
69. Krum H., Schlaich M.P., Sobotka P.A., et al. Percutaneous renal denervation in patients with treatment-resistant hypertension: final 3-year report of the Symplicity HTN-1 study. Lancet 2014, 383:622-629.
70. Bhatt D.L., Kandzari D.E., O'Neill W.W., et al. A controlled trial of renal denervation for resistant hypertension. N Engl J Med 2014, 370:1393-1401.
71. Iliescu R., Lohmeier T.E., Tudorancea I., et al. Renal denervation for the treatment of resistant hypertension: review and clinical perspective. Am J Physiol Renal Physiol 2015, 309:F583-F594.
72. Kandzari D.E., Bhatt D.L., Brar S., et al. Predictors of blood pressure response in the SYMPLICITY HTN-3 trial. Eur Heart J 2015, 36:219-227.
73. Henegar J.R., Zhang Y., Rama R.D., et al. Catheter-based radiorefrequency renal denervation lowers blood pressure in obese hypertensive dogs. Am J Hypertens 2014, 27:1285-1292.
74. Krum H., Schlaich M., Whitbourn R., et al. Catheter-based renal sympathetic denervation for resistant hypertension: a multicentre safety and proof-of-principle cohort study. Lancet 2009, 373:1275-1281.
75. Henegar J.R., Zhang Y., Hata C., et al. Catheter-Based Radiofrequency Renal Denervation: Location Effects on Renal Norepinephrine. Am J Hypertens 2015, 28:909-914.
76. Mulder J., Hokfelt T., Knuepfer M.M., et al. Renal sensory and sympathetic nerves reinnervate the kidney in a similar time-dependent fashion after renal denervation in rats. Am J Physiol Regul Integr Comp Physiol 2013, 304:R675-R682.
77. Malpas S.C. Sympathetic nervous system overactivity and its role in the development of cardiovascular disease. Physiol Rev 2010, 90:513-557.
78. Lohmeier T.E., Iliescu R. The baroreflex as a long-term controller of arterial pressure. Physiology (Bethesda) 2015, 30:148-158.
79. Osborn J.W., Provo B.J. Salt-dependent hypertension in the sinoaortic-denervated rat. Hypertension 1992, 19:658-662.
80. Lohmeier T.E., Iliescu R., Liu B., et al. Systemic and renal-specific sympathoinhibition in obesity hypertension. Hypertension 2012, 59:331-338.
81. Wustmann K., Kucera J.P., Scheffers I., et al. Effects of chronic baroreceptor stimulation on the autonomic cardiovascular regulation in patients with drug-resistant arterial hypertension. Hypertension 2009, 54:530-536.
82. Orfila C., Damase-Michel C., Lepert J.C., et al. Renal morphological changes after sinoaortic denervation in dogs. Hypertension 1993, 21:758-766.
83. Van Vliet B.N., Hu L., Scott T., et al. Cardiac hypertrophy and telemetered blood pressure 6 wk after baroreceptor denervation in normotensive rats. Am J Physiol 1996, 271:R1759-R1769.
84. Guyenet P.G. Regulation of breathing and autonomic outflows by chemoreceptors. Compr Physiol 2014, 4:1511-1562.
85. McBryde F.D., Abdala A.P., Hendy E.B., et al. The carotid body as a putative therapeutic target for the treatment of neurogenic hypertension. Nat Commun 2013, 4:2395.
86. Paton J.F., Sobotka P.A., Fudim M., et al. The carotid body as a therapeutic target for the treatment of sympathetically mediated diseases. Hypertension 2013, 61:5-13.
87. Sinski M., Lewandowski J., Przybylski J., et al. Tonic activity of carotid body chemoreceptors contributes to the increased sympathetic drive in essential hypertension. Hypertens Res 2012, 35:487-491.
88. Oparil S., Schmieder R.E. New approaches in the treatment of hypertension. Circ Res 2015, 116:1074-1095.
89. Narkiewicz K., van de Borne P.J., Montano N., et al. Contribution of tonic chemoreflex activation to sympathetic activity and blood pressure in patients with obstructive sleep apnea. Circulation 1998, 97:943-945.
90. Verbraecken J., McNicholas W.T. Respiratory mechanics and ventilatory control in overlap syndrome and obesity hypoventilation. Respir Res 2013, 14:132.
91. Salome C.M., King G.G., Berend N. Physiology of obesity and effects on lung function. J Appl Physiol 1985, 2010(108):206-211.
92. Lohmeier T.E., Iliescu R., Tudorancea I., et al. Chronic interactions between carotid baroreceptors and chemoreceptors in obesity hypertension. Hypertension 2016, 68:227-235.
93. Dhaun N., Goddard J., Kohan D.E., et al. Role of endothelin-1 in clinical hypertension: 20 years on. Hypertension 2008, 52:452-459.
94. Granger J.P., Abram S., Stec D., et al. Endothelin, the kidney, and hypertension. Curr Hypertens Rep 2006, 8:298-303.
95. LaMarca B.D., Alexander B.T., Gilbert J.S., et al. Pathophysiology of hypertension in response to placental ischemia during pregnancy: a central role for endothelin?. Gend Med 2008, 5(Suppl A):S133-S138.
96. Granger J.P. Endothelin. Am J Physiol Regul Integr Comp Physiol 2003, 285:R298-R301.
97. Ihara M., Noguchi K., Saeki T., et al. Biological profiles of highly potent novel endothelin antagonists selective for the ETA receptor. Life Sci 1992, 50:247-255.
98. Davenport A.P., Hyndman K.A., Dhaun N., et al. Endothelin. Pharmacol Rev 2016, 68:357-418.
99. Kassab S., Novak J., Miller T., et al. Role of endothelin in mediating the attenuated renal hemodynamics in Dahl salt-sensitive hypertension. Hypertension 1997, 30:682-686.
100. Alexander B.T., Cockrell K.L., Rinewalt A.N., et al. Enhanced renal expression of preproendothelin mRNA during chronic angiotensin II hypertension. Am J Physiol Regul Integr Comp Physiol 2001, 280:R1388-R1392.
101. Ballew J.R., Fink G.D. Role of ET(A) receptors in experimental ANG II-induced hypertension in rats. Am J Physiol Regul Integr Comp Physiol 2001, 281:R150-R154.
102. De M.C., Pollock D.M., Pollock J.S. Endothelium-derived ET-1 and the development of renal injury. Am J Physiol Regul Integr Comp Physiol 2015, 309:R1071-R1073.
103. Kassab S., Miller M.T., Novak J., et al. Endothelin-A receptor antagonism attenuates the hypertension and renal injury in Dahl salt-sensitive rats. Hypertension 1998, 31:397-402.
104. d'Uscio L.V., Moreau P., Shaw S., et al. Effects of chronic ETA-receptor blockade in angiotensin II-induced hypertension. Hypertension 1997, 29:435-441.
105. Lin H., Smith M.J., Young D.B. Roles of prostaglandins and nitric oxide in the effect of endothelin-1 on renal hemodynamics. Hypertension 1996, 28:372-378.
106. Laffin L.J., Bakris G.L. Endothelin antagonism and hypertension: an evolving target. Semin Nephrol 2015, 35:168-175.
107. Kohan D.E. The renal medullary endothelin system in control of sodium and water excretion and systemic blood pressure. Curr Opin Nephrol Hypertens 2006, 15:34-40.
108. Gariepy C.E., Cass D.T., Yanagisawa M. Null mutation of endothelin receptor type B gene in spotting lethal rats causes aganglionic megacolon and white coat color. Proc Natl Acad Sci U S A 1996, 93:867-872.
109. Gariepy C.E., Ohuchi T., Williams S.C., et al. Salt-sensitive hypertension in endothelin-B receptor-deficient rats. J Clin Invest 2000, 105:925-933.
110. Pollock D.M., Pollock J.S. Evidence for endothelin involvement in the response to high salt. Am J Physiol Renal Physiol 2001, 281:F144-F150.
111. Schneider M.P., Ge Y., Pollock D.M., et al. Collecting duct-derived endothelin regulates arterial pressure and Na excretion via nitric oxide. Hypertension 2008, 51:1605-1610.
112. Plato C.F., Pollock D.M., Garvin J.L. Endothelin inhibits thick ascending limb chloride flux via ET(B) receptor-mediated NO release. Am J Physiol Renal Physiol 2000, 279:F326-F333.
113. Hocher B., Thone-Reineke C., Rohmeiss P., et al. Endothelin-1 transgenic mice develop glomerulosclerosis, interstitial fibrosis, and renal cysts but not hypertension. J Clin Invest 1997, 99:1380-1389.
114. Miyagawa K., Emoto N. Current state of endothelin receptor antagonism in hypertension and pulmonary hypertension. Ther Adv Cardiovasc Dis 2014, 8:202-216.
115. Weber M.A., Black H., Bakris G., et al. A selective endothelin-receptor antagonist to reduce blood pressure in patients with treatment-resistant hypertension: a randomised, double-blind, placebo-controlled trial. Lancet 2009, 374:1423-1431.
116. Ito S., Juncos L.A., Nushiro N., et al. Endothelium-derived relaxing factor modulates endothelin action in afferent arterioles. Hypertension 1991, 17:1052-1056.
117. Lerman A., Sandok E.K., Hildebrand F.L., et al. Inhibition of endothelium-derived relaxing factor enhances endothelin-mediated vasoconstriction. Circulation 1992, 85:1894-1898.
118. Rapoport R.M. Nitric oxide inhibition of endothelin-1 release in the vasculature: in vivo relevance of in vitro findings. Hypertension 2014, 64:908-914.
119. Cowley A.W., Mori T., Mattson D., et al. Role of renal NO production in the regulation of medullary blood flow. Am J Physiol Regul Integr Comp Physiol 2003, 284:R1355-R1369. 2003.
120. Schnackenberg C., Patel A.R., Kirchner K.A., et al. Nitric oxide, the kidney and hypertension. Clin Exp Pharmacol Physiol 1997, 24:600-606.
121. Ortiz P.A., Garvin J.L. Role of nitric oxide in the regulation of nephron transport. Am J Physiol Renal Physiol 2002, 282:F777-F784.
122. Lu Y., Wei J., Stec D.E., et al. Macula Densa Nitric Oxide Synthase 1beta Protects against Salt-Sensitive Hypertension. J Am Soc Nephrol 2016, 27:2346-2356.
123. Granger J.P., Alexander B.T. Abnormal pressure-natriuresis in hypertension: role of nitric oxide. Acta Physiol Scand 2000, 168:161-168.
124. Brown K.E., Dhaun N., Goddard J., et al. Potential therapeutic role of phosphodiesterase type 5 inhibition in hypertension and chronic kidney disease. Hypertension 2014, 63:5-11.
125. Sinha N., Dabla P.K. Oxidative stress and antioxidants in hypertension-a current review. Curr Hypertens Rev 2015, 11:132-142.
126. Hamza S.M., Dyck J.R. Systemic and renal oxidative stress in the pathogenesis of hypertension: modulation of long-term control of arterial blood pressure by resveratrol. Front Physiol 2014, 5:292.
127. Rajagopalan S., Kurz S., Munzel T., et al. Angiotensin II-mediated hypertension in the rat increases vascular superoxide production via membrane NADH/NADPH oxidase activation. Contribution to alterations of vasomotor tone. J Clin Invest 1996, 97:1916-1923.
128. Cowley A.W., Abe M., Mori T., et al. Reactive oxygen species as important determinants of medullary flow, sodium excretion, and hypertension. Am J Physiol Renal Physiol 2015, 308:F179-F197.
129. Park J.B., Touyz R.M., Chen X., et al. Chronic treatment with a superoxide dismutase mimetic prevents vascular remodeling and progression of hypertension in salt-loaded stroke-prone spontaneously hypertensive rats. Am J Hypertens 2002, 15:78-84.
130. Tabet F., Savoia C., Schiffrin E.L., et al. Differential calcium regulation by hydrogen peroxide and superoxide in vascular smooth muscle cells from spontaneously hypertensive rats. J Cardiovasc Pharmacol 2004, 44:200-208.
131. Lacy F., O'Connor D.T., Schmid-Schonbein G.W. Plasma hydrogen peroxide production in hypertensives and normotensive subjects at genetic risk of hypertension. J Hypertens 1998, 16:291-303.
132. Dikalov S., Griendling K.K., Harrison D.G. Measurement of reactive oxygen species in cardiovascular studies. Hypertension 2007, 49:717-727.
133. Pechanova O., Simko F. Chronic antioxidant therapy fails to ameliorate hypertension: potential mechanisms behind. J Hypertens Suppl 2009, 27:S32-S36.
134. Montezano A.C., Touyz R.M. Molecular mechanisms of hypertension-reactive oxygen species and antioxidants: a basic science update for the clinician. Can J Cardiol 2012, 28:288-295.
135. Weseler A.R., Bast A. Oxidative stress and vascular function: implications for pharmacologic treatments. Curr Hypertens Rep 2010, 12:154-161.
136. Chen S., Ge Y., Si J., et al. Candesartan suppresses chronic renal inflammation by a novel antioxidant action independent of AT1R blockade. Kidney Int 2008, 74:1128-1138.
137. Kupper N., Willemsen G., Riese H., et al. Heritability of daytime ambulatory blood pressure in an extended twin design. Hypertension 2005, 45:80-85.
138. Padmanabhan S., Caulfield M., Dominiczak A.F. Genetic and molecular aspects of hypertension. Circ Res 2015, 116:937-959.
139. Longini I.M., Higgins M.W., Hinton P.C., et al. Environmental and genetic sources of familial aggregation of blood pressure in Tecumseh, Michigan. Am J Epidemiol 1984, 120:131-144.
140. Cui J., Hopper J.L., Harrap S.B. Genes and family environment explain correlations between blood pressure and body mass index. Hypertension 2002, 40:7-12.
141. Luft F.C. Molecular genetics of human hypertension. J Hypertens 1998, 16:1871-1878.
142. Luft F.C. Geneticism of essential hypertension. Hypertension 2004, 43:1155-1159.
143. Levy D., Ehret G.B., Rice K., et al. Genome-wide association study of blood pressure and hypertension. Nat Genet 2009, 41:677-687.
144. Newton-Cheh C., Johnson T., Gateva V., et al. Genome-wide association study identifies eight loci associated with blood pressure. Nat Genet 2009, 41:666-676.
145. Ehret G.B., Munroe P.B., Rice K.M., et al. Genetic variants in novel pathways influence blood pressure and cardiovascular disease risk. Nature 2011, 478:103-109.
146. Cowley A.W., Nadeau J.H., Baccarelli A., et al. Report of the National Heart, Lung, and Blood Institute Working Group on epigenetics and hypertension. Hypertension 2012, 59:899-905.
147. Feinberg A.P., Fallin M.D. Epigenetics at the Crossroads of Genes and the Environment. JAMA 2015, 314:1129-1130.
148. Kotchen T.A., Cowley A.W., Liang M. Ushering Hypertension into a New Era of Precision Medicine. JAMA 2016, 315:343-344.
149. World Health Organization Obesity and Overweight Fact Sheet N°311 http://www.who.int/mediacentre/factsheets/fs311/en/2014.
150. U.S. Department of Health and Human Services-Center for Disease Control and Prevention Overweight & Obesity Data & Statistics 2014, http://www.cdc.gov/obesity/data/index.html.
151. Ogden C.L., Carroll M.D., Kit B.K., et al. Prevalence of childhood and adult obesity in the United States, 2011-2012. JAMA 2014, 311:806-814.
152. Jones D.W., Kim J.S., Andrew M.E., et al. Body mass index and blood pressure in Korean men and women: the Korean National Blood Pressure Survey. J Hypertens 1994, 12:1433-1437.
153. Jones D.W., Miller M.E., Wofford M.R., et al. The effect of weight loss intervention on antihypertensive medication requirements in the hypertension Optimal Treatment (HOT) study. Am J Hypertens 1999, 12:1175-1180.
154. Stevens V.J., Obarzanek E., Cook N.R., et al. Long-term weight loss and changes in blood pressure: results of the Trials of Hypertension Prevention, phase II. Ann Intern Med 2001, 134:1-11.
155. Hall J.E., Crook E.D., Jones D.W., et al. Mechanisms of obesity-associated cardiovascular and renal disease. Am J Med Sci 2002, 324:127-137.
156. Tchernof A., Despres J.P. Pathophysiology of human visceral obesity: an update. Physiol Rev 2013, 93:359-404.
157. Hall J.E., Brands M.W., Dixon W.N., et al. Obesity-induced hypertension. Renal function and systemic hemodynamics. Hypertension 1993, 22:292-299.
158. Messerli F.H., Christie B., DeCarvalho J.G., et al. Obesity and essential hypertension. Hemodynamics, intravascular volume, sodium excretion, and plasma renin activity. Arch Intern Med 1981, 141:81-85.
159. Lyon C.J., Law R.E., Hsueh W.A. Minireview: adiposity, inflammation, and atherogenesis. Endocrinology 2003, 144:2195-2200.
160. Hall J.E. Mechanisms of abnormal renal sodium handling in obesity hypertension. Am J Hypertens 1997, 10:49S-55S.
161. Hall M.E., do Carmo J.M., da Silva A.A., et al. Obesity, hypertension, and chronic kidney disease. Int J Nephrol Renovasc Dis 2014, 7:75-88.
162. Sugerman H., Windsor A., Bessos M., et al. Intra-abdominal pressure, sagittal abdominal diameter and obesity comorbidity. J Intern Med 1997, 241:71-79.
163. Chandra A., Neeland I.J., Berry J.D., et al. The relationship of body mass and fat distribution with incident hypertension: observations from the Dallas heart study. J Am Coll Cardiol 2014, 64:997-1002.
164. Chughtai H.L., Morgan T.M., Rocco M., et al. Renal sinus fat and poor blood pressure control in middle-aged and elderly individuals at risk for cardiovascular events. Hypertension 2010, 56:901-906.
165. DeMarco V.G., Aroor A.R., Sowers J.R. The pathophysiology of hypertension in patients with obesity. Nat Rev Endocrinol 2014, 10:364-376.
166. Putnam K., Shoemaker R., Yiannikouris F., et al. The renin-angiotensin system: a target of and contributor to dyslipidemias, altered glucose homeostasis, and hypertension of the metabolic syndrome. Am J Physiol Heart Circ Physiol 2012, 302:H1219-H1230.
167. Engeli S., Sharma A.M. The renin-angiotensin system and natriuretic peptides in obesity-associated hypertension. J Mol Med 2001, 79:21-29.
168. Marcus Y., Shefer G., Stern N. Adipose tissue renin-angiotensin-aldosterone system (RAAS) and progression of insulin resistance. Mol Cell Endocrinol 2013, 378:1-14.
169. Boustany C.M., Brown D.R., Randall D.C., et al. AT1-receptor antagonism reverses the blood pressure elevation associated with diet-induced obesity. Am J Physiol Regul Integr Comp Physiol 2005, 289:R181-R186.
170. Robles R.G., Villa E., Santirso R., et al. Effects of captopril on sympathetic activity, lipid and carbohydrate metabolism in a model of obesity-induced hypertension in dogs. Am J Hypertens 1993, 6:1009-1015.
171. Alonso-Galicia M., Brands M.W., Zappe D.H., et al. Hypertension in obese Zucker rats. Role of angiotensin II and adrenergic activity. Hypertension 1996, 28:1047-1054.
172. Dorresteijn J.A., Schrover I.M., Visseren F.L., et al. Differential effects of renin-angiotensin-aldosterone system inhibition, sympathoinhibition and diuretic therapy on endothelial function and blood pressure in obesity-related hypertension: a double-blind, placebo-controlled cross-over trial. J Hypertens 2013, 31:393-403.
173. Grassi G., Seravalle G., Dell'Oro R., et al. Comparative effects of candesartan and hydrochlorothiazide on blood pressure, insulin sensitivity, and sympathetic drive in obese hypertensive individuals: results of the CROSS study. J Hypertens 2003, 21:1761-1769.
174. Reisin E., Weir M.R., Falkner B., et al. Lisinopril versus hydrochlorothiazide in obese hypertensive patients: a multicenter placebo-controlled trial. Treatment in Obese Patients with Hypertension (TROPHY) Study Group. Hypertension 1997, 30:140-145.
175. Lewis E.J., Hunsicker L.G., Clarke W.R., et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001, 345:851-860.
176. Brenner B.M., Cooper M.E., de Z.D., et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001, 345:861-869.
177. de Paula R.B., da Silva A.A., Hall J.E. Aldosterone antagonism attenuates obesity-induced hypertension and glomerular hyperfiltration. Hypertension 2004, 43:41-47.
178. Bickel C.A., Verbalis J.G., Knepper M.A., et al. Increased renal Na-K-ATPase, NCC, and beta-ENaC abundance in obese Zucker rats. Am J Physiol Renal Physiol 2001, 281:F639-F648.
179. Funder J.W. Reconsidering the roles of the mineralocorticoid receptor. Hypertension 2009, 53:286-290.
180. Hall J.E., da Silva A.A., do Carmo J.M., et al. Obesity-induced hypertension: role of sympathetic nervous system, leptin, and melanocortins. J Biol Chem 2010, 285:17271-17276.
181. Carlyle M., Jones O.B., Kuo J.J., et al. Chronic cardiovascular and renal actions of leptin: role of adrenergic activity. Hypertension 2002, 39:496-501.
182. Wofford M.R., Anderson D.C., Brown C.A., et al. Antihypertensive effect of alpha- and beta-adrenergic blockade in obese and lean hypertensive subjects. Am J Hypertens 2001, 14:694-698.
183. da Silva A.A., do Carmo J.M., Wang Z., et al. The brain melanocortin system, sympathetic control, and obesity hypertension. Physiology (Bethesda) 2014, 29:196-202.
184. do Carmo J.M., da Silva A.A., Dubinion J., et al. Control of metabolic and cardiovascular function by the leptin-brain melanocortin pathway. IUBMB Life 2013, 65:692-698.
185. da Silva A.A., do Carmo J.M., Hall J.E. Role of leptin and central nervous system melanocortins in obesity hypertension. Curr Opin Nephrol Hypertens 2013, 22:135-140.
186. Machleidt F., Simon P., Krapalis A.F., et al. Experimental hyperleptinemia acutely increases vasoconstrictory sympathetic nerve activity in healthy humans. J Clin Endocrinol Metab 2013, 98:E491-E496.
187. Shek E.W., Brands M.W., Hall J.E. Chronic leptin infusion increases arterial pressure. Hypertension 1998, 31:409-414.
188. Kuo J.J., Jones O.B., Hall J.E. Inhibition of NO synthesis enhances chronic cardiovascular and renal actions of leptin. Hypertension 2001, 37:670-676.
189. Lim K., Burke S.L., Head G.A. Obesity-related hypertension and the role of insulin and leptin in high-fat-fed rabbits. Hypertension 2013, 61:628-634.
190. Ozata M., Ozdemir I.C., Licinio J. Human leptin deficiency caused by a missense mutation: multiple endocrine defects, decreased sympathetic tone, and immune system dysfunction indicate new targets for leptin action, greater central than peripheral resistance to the effects of leptin, and spontaneous correction of leptin-mediated defects. J Clin Endocrinol Metab 1999, 84:3686-3695.
191. Cone R.D. Studies on the physiological functions of the melanocortin system. Endocr 2006, 27:736-749.
192. Kuo J.J., Silva A.A., Hall J.E. Hypothalamic melanocortin receptors and chronic regulation of arterial pressure and renal function. Hypertension 2003, 41:768-774.
193. Kuo J.J., da Silva A.A., Tallam L.S., et al. Role of adrenergic activity in pressor responses to chronic melanocortin receptor activation. Hypertension 2004, 43:370-375.
194. Greenfield J.R. Melanocortin signalling and the regulation of blood pressure in human obesity. J Neuroendocrinol 2011, 23:186-193.
195. da Silva A.A., do Carmo J.M., Kanyicska B., et al. Endogenous melanocortin system activity contributes to the elevated arterial pressure in spontaneously hypertensive rats. Hypertension 2008, 51:884-890.
196. Tallam L.S., da Silva A.A., Hall J.E. Melanocortin-4 receptor mediates chronic cardiovascular and metabolic actions of leptin. Hypertension 2006, 48:58-64.
197. Greenfield J.R., Miller J.W., Keogh J.M., et al. Modulation of blood pressure by central melanocortinergic pathways. N Engl J Med 2009, 360:44-52.
198. do Carmo J.M., da Silva A.A., Cai Z., et al. Control of blood pressure, appetite, and glucose by leptin in mice lacking leptin receptors in proopiomelanocortin neurons. Hypertension 2011, 57:918-926.
199. Burton J.O., Gray L.J., Webb D.R., et al. Association of anthropometric obesity measures with chronic kidney disease risk in a non-diabetic patient population. Nephrol Dial Transplant 2012, 27:1860-1866.
200. Hsu C.Y., McCulloch C.E., Iribarren C., et al. Body mass index and risk for end-stage renal disease. Ann Intern Med 2006, 144:21-28.
201. Amann K., Benz K. Structural renal changes in obesity and diabetes. Semin Nephrol 2013, 33:23-33.
202. Hall J.E., Henegar J.R., Dwyer T.M., et al. Is obesity a major cause of chronic kidney disease?. Adv Ren Replace Ther 2004, 11:41-54.
203. Henegar J.R., Bigler S.A., Henegar L.K., et al. Functional and structural changes in the kidney in the early stages of obesity. J Am Soc Nephrol 2001, 12:1211-1217.
204. Egan B.M., Li J. Role of aldosterone blockade in resistant hypertension. Semin Nephrol 2014, 34:273-284.
205. Chapman N., Dobson J., Wilson S., et al. Effect of spironolactone on blood pressure in subjects with resistant hypertension. Hypertension 2007, 49:839-845.
206. McMaster W.G., Kirabo A., Madhur M.S., et al. Inflammation, immunity, and hypertensive end-organ damage. Circ Res 2015, 116:1022-1033.